TDOC - NYSE
Teladoc Health, Inc.
$7.09
-6.0%Teladoc Health, Inc. provides virtual healthcare services in the United States and internationally. The company offers a portfolio of services and solutions covering non-urgent, episodic, chronic, and complicated medical conditions, including diabetes, hypertension, chronic kidney disease, cancer, congestive heart failure, and mental health conditions. It offers a range of programs and services, including primary and specialty care telehealth solutions, chronic condition management, expert medical services, mental health solutions, and platform and program services. The company serves employers, health plans, hospitals and health systems, and insurance and financial services companies, as well as individual members. It offers its products and services under the Teladoc, Livongo, and BetterHelp brands. The company was formerly known as Teladoc, Inc. and changed its name to Teladoc Health, Inc. in August 2018. The company was incorporated in 2002 and is headquartered in Purchase, New York.
At a Glance
Live SnapshotTeladoc Health, Inc. Management Team
Mr. Chris Stenrud
Chief Communications & Brand Officer
Mr. Charles Divita III, CPA
Chief Executive Officer & Director
Compensation
$1,389,037
Ms. Mala Murthy
Chief Financial Officer
Compensation
$800,052
Mr. Adam Christian Vandervoort J.D.
Chief Legal Officer & Secretary
Compensation
$704,467
Mr. Nikolaos Nanis
Chief Technology Officer
Dr. George Byron Brooks BS EE, M.D.
Co-Founder
Mr. Carlos Nueno
President of International
Compensation
$1,095,608
Ms. Kelly M. Bliss
President of U.S. Group Health
Compensation
$762,241
Mr. Joseph Ronald Catapano Cpa
Senior Vice President & Chief Accounting Officer
Michael Minchak
Vice President of Investor Relations
Teladoc Health, Inc. Insider Positioning
During the last 12 months, insiders have purchased $69K and sold $1.39M worth of TDOC shares, resulting in $1.32M of net selling activity.
3 Months
0
0.00
28.4K
155.69K
-156K
-$156K
3-6 Months
0
0.00
123.1K
674.60K
-675K
-$675K
6-9 Months
10.0K
69.40K
40.5K
306.07K
-237K
-$237K
9-12 Months
0
0.00
33.9K
257.48K
-257K
-$257K
Top Buyers
Paulus Kenneth H
Director
$69K
Top Sellers
Divita Charles Iii
Director, Officer: Chief Executive Officer
$667K
Vandervoort Adam C
Officer: Chief Legal Officer, Secretary
$226K
Bliss Kelly
Officer: President, U.S. Group Health
$206K
Rodrigues Fernando M.
Officer: President Of Betterhelp
$98K
Murthy Mala
Officer: Chief Financial Officer
$97K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $1.32M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider sellers vs. 1 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
SEC Filings
TDOC - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 07, 2026 | May 21, 2026 | 2026 | |
DEF 14A DEF 14A 2024 N/A | April 08, 2025 | December 31, 2024 | 2024 | |
DEF 14A DEF 14A 2024 N/A | April 09, 2024 | May 23, 2024 | 2024 | |
DEF 14A DEF 14A N/A | April 11, 2023 | April 11, 2023 | ||
DEF 14A DEF 14A 2022 N/A | April 12, 2022 | May 26, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 07, 2021 | May 17, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 14, 2020 | May 28, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 19, 2019 | May 30, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 20, 2018 | May 31, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | April 06, 2017 | May 25, 2017 | 2017 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.